<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05389722</url>
  </required_header>
  <id_info>
    <org_study_id>CA057-002</org_study_id>
    <nct_id>NCT05389722</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Parallel-group, 3-part, 2-period, Fixed-sequence, Crossover, Open-label, Nonrandomized, Drug-drug Interaction Study to Assess the Pharmacokinetics of CC-92480 (BMS-986348) After Coadministration With Rifampin and Itraconazole, and Pharmacokinetics of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug levels of CC-92480 after coadministration&#xD;
      with rifampin and itraconazole and the drug levels of digoxin and rosuvastatin after&#xD;
      coadministration with CC-92480 in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2022</start_date>
  <completion_date type="Actual">November 12, 2022</completion_date>
  <primary_completion_date type="Actual">November 12, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))</measure>
    <time_frame>Up to 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination findings</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-92480</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
    <other_name>BMS-986348</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have a body mass index between 18 and 33 kg/m2 (inclusive)&#xD;
&#xD;
          -  Adult female of nonchildbearing potential or male, any race or ethnicity, and in good&#xD;
             health as determined by the medical history, physical exam, vital signs, 12-lead&#xD;
             electrocardiogram, and clinical laboratory assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any surgical or medical condition possibly affecting drug absorption, distribution,&#xD;
             metabolism, and excretion&#xD;
&#xD;
          -  Any major surgery within 4 weeks of the first dose administration&#xD;
&#xD;
          -  History of drug abuse within 2 years of the first dose administration&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247-4968</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>May 20, 2022</study_first_submitted>
  <study_first_submitted_qc>May 20, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2022</study_first_posted>
  <last_update_submitted>April 18, 2023</last_update_submitted>
  <last_update_submitted_qc>April 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CC-92480</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

